Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants

Tatsuhiko Ozawa; Hideki Tani; Yuki Anraku; Shunsuke Kita; Emiko Igarashi; Yumiko Saga; Noriko Inasaki; Hitoshi Kawasuji; Hiroshi Yamada; so Ichiro Sasaki; Mayu Somekawa; Jiei Sasaki; Yoshihiro Hayakawa; Yoshihiro Yamamoto; Yoshitomo Morinaga; Nobuyuki Kurosawa; Masaharu Isobe; Hideo Fukuhara; Katsumi Maenaka; Takao Hashiguchi; Hiroyuki Kishi; Isao Kitajima; Shigeru Saito; Hideki Niimi

doi:10.1080/19420862.2022.2072455

Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants

Tatsuhiko Ozawa^*, Hideki Tani, Yuki Anraku, Shunsuke Kita, Emiko Igarashi, Yumiko Saga, Noriko Inasaki, Hitoshi Kawasuji, Hiroshi Yamada, so Ichiro Sasaki, Mayu Somekawa, Jiei Sasaki, Yoshihiro Hayakawa, Yoshihiro Yamamoto, Yoshitomo Morinaga, Nobuyuki Kurosawa, Masaharu Isobe, Hideo Fukuhara, Katsumi Maenaka, Takao HashiguchiHiroyuki Kishi, Isao Kitajima, Shigeru Saito, Hideki Niimi^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Many potent neutralizing SARS-CoV-2 antibodies have been developed and used for therapies. However, the effectiveness of many antibodies has been reduced against recently emerging SARS-CoV-2 variants, especially the Omicron variant. We identified a highly potent SARS-CoV-2 neutralizing antibody, UT28K, in COVID-19 convalescent individuals who recovered from a severe condition. UT28K showed efficacy in neutralizing SARS-CoV-2 in an in vitro assay and in vivo prophylactic treatment, and the reactivity to the Omicron strain was reduced. The structural analyses revealed that antibody UT28K Fab and SARS-CoV-2 RBD protein interactions were mainly chain-dominated antigen-antibody interactions. In addition, a mutation analysis suggested that the emergence of a UT28K neutralization-resistant SARS-CoV-2 variant was unlikely, as this variant would likely lose its competitive advantage over circulating SARS-CoV-2. Our data suggest that UT28K offers potent protection against SARS-CoV-2, including newly emerging variants.

Original language	English
Article number	2072455
Journal	mAbs
Volume	14
Issue number	1
DOIs	https://doi.org/10.1080/19420862.2022.2072455
State	Published - 2022

Keywords

COVID-19
SARS-CoV-2
monoclonal antibody
neutralizing antibody
super-neutralizing antibody

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1080/19420862.2022.2072455

Cite this

Ozawa, T., Tani, H., Anraku, Y., Kita, S., Igarashi, E., Saga, Y., Inasaki, N., Kawasuji, H., Yamada, H., Sasaki, S. I., Somekawa, M., Sasaki, J., Hayakawa, Y., Yamamoto, Y., Morinaga, Y., Kurosawa, N., Isobe, M., Fukuhara, H., Maenaka, K., ... Niimi, H. (2022). Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants. mAbs, 14(1), Article 2072455. https://doi.org/10.1080/19420862.2022.2072455

@article{864670721af64656b0753d97c910262f,

title = "Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants",

abstract = "Many potent neutralizing SARS-CoV-2 antibodies have been developed and used for therapies. However, the effectiveness of many antibodies has been reduced against recently emerging SARS-CoV-2 variants, especially the Omicron variant. We identified a highly potent SARS-CoV-2 neutralizing antibody, UT28K, in COVID-19 convalescent individuals who recovered from a severe condition. UT28K showed efficacy in neutralizing SARS-CoV-2 in an in vitro assay and in vivo prophylactic treatment, and the reactivity to the Omicron strain was reduced. The structural analyses revealed that antibody UT28K Fab and SARS-CoV-2 RBD protein interactions were mainly chain-dominated antigen-antibody interactions. In addition, a mutation analysis suggested that the emergence of a UT28K neutralization-resistant SARS-CoV-2 variant was unlikely, as this variant would likely lose its competitive advantage over circulating SARS-CoV-2. Our data suggest that UT28K offers potent protection against SARS-CoV-2, including newly emerging variants.",

keywords = "COVID-19, SARS-CoV-2, monoclonal antibody, neutralizing antibody, super-neutralizing antibody",

author = "Tatsuhiko Ozawa and Hideki Tani and Yuki Anraku and Shunsuke Kita and Emiko Igarashi and Yumiko Saga and Noriko Inasaki and Hitoshi Kawasuji and Hiroshi Yamada and Sasaki, {so Ichiro} and Mayu Somekawa and Jiei Sasaki and Yoshihiro Hayakawa and Yoshihiro Yamamoto and Yoshitomo Morinaga and Nobuyuki Kurosawa and Masaharu Isobe and Hideo Fukuhara and Katsumi Maenaka and Takao Hashiguchi and Hiroyuki Kishi and Isao Kitajima and Shigeru Saito and Hideki Niimi",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2022",

doi = "10.1080/19420862.2022.2072455",

language = "英語",

volume = "14",

journal = "mAbs",

issn = "1942-0862",

number = "1",

}

Ozawa, T, Tani, H, Anraku, Y, Kita, S, Igarashi, E, Saga, Y, Inasaki, N, Kawasuji, H , Yamada, H , Sasaki, SI, Somekawa, M, Sasaki, J, Hayakawa, Y , Yamamoto, Y , Morinaga, Y , Kurosawa, N , Isobe, M, Fukuhara, H, Maenaka, K, Hashiguchi, T, Kishi, H , Kitajima, I , Saito, S & Niimi, H 2022, 'Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants', mAbs, vol. 14, no. 1, 2072455. https://doi.org/10.1080/19420862.2022.2072455

TY - JOUR

T1 - Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants

AU - Ozawa, Tatsuhiko

AU - Tani, Hideki

AU - Anraku, Yuki

AU - Kita, Shunsuke

AU - Igarashi, Emiko

AU - Saga, Yumiko

AU - Inasaki, Noriko

AU - Kawasuji, Hitoshi

AU - Yamada, Hiroshi

AU - Sasaki, so Ichiro

AU - Somekawa, Mayu

AU - Sasaki, Jiei

AU - Hayakawa, Yoshihiro

AU - Yamamoto, Yoshihiro

AU - Morinaga, Yoshitomo

AU - Kurosawa, Nobuyuki

AU - Isobe, Masaharu

AU - Fukuhara, Hideo

AU - Maenaka, Katsumi

AU - Hashiguchi, Takao

AU - Kishi, Hiroyuki

AU - Kitajima, Isao

AU - Saito, Shigeru

AU - Niimi, Hideki

PY - 2022

Y1 - 2022

N2 - Many potent neutralizing SARS-CoV-2 antibodies have been developed and used for therapies. However, the effectiveness of many antibodies has been reduced against recently emerging SARS-CoV-2 variants, especially the Omicron variant. We identified a highly potent SARS-CoV-2 neutralizing antibody, UT28K, in COVID-19 convalescent individuals who recovered from a severe condition. UT28K showed efficacy in neutralizing SARS-CoV-2 in an in vitro assay and in vivo prophylactic treatment, and the reactivity to the Omicron strain was reduced. The structural analyses revealed that antibody UT28K Fab and SARS-CoV-2 RBD protein interactions were mainly chain-dominated antigen-antibody interactions. In addition, a mutation analysis suggested that the emergence of a UT28K neutralization-resistant SARS-CoV-2 variant was unlikely, as this variant would likely lose its competitive advantage over circulating SARS-CoV-2. Our data suggest that UT28K offers potent protection against SARS-CoV-2, including newly emerging variants.

AB - Many potent neutralizing SARS-CoV-2 antibodies have been developed and used for therapies. However, the effectiveness of many antibodies has been reduced against recently emerging SARS-CoV-2 variants, especially the Omicron variant. We identified a highly potent SARS-CoV-2 neutralizing antibody, UT28K, in COVID-19 convalescent individuals who recovered from a severe condition. UT28K showed efficacy in neutralizing SARS-CoV-2 in an in vitro assay and in vivo prophylactic treatment, and the reactivity to the Omicron strain was reduced. The structural analyses revealed that antibody UT28K Fab and SARS-CoV-2 RBD protein interactions were mainly chain-dominated antigen-antibody interactions. In addition, a mutation analysis suggested that the emergence of a UT28K neutralization-resistant SARS-CoV-2 variant was unlikely, as this variant would likely lose its competitive advantage over circulating SARS-CoV-2. Our data suggest that UT28K offers potent protection against SARS-CoV-2, including newly emerging variants.

KW - COVID-19

KW - SARS-CoV-2

KW - monoclonal antibody

KW - neutralizing antibody

KW - super-neutralizing antibody

UR - http://www.scopus.com/inward/record.url?scp=85130001575&partnerID=8YFLogxK

U2 - 10.1080/19420862.2022.2072455

DO - 10.1080/19420862.2022.2072455

M3 - 学術論文

C2 - 35543180

AN - SCOPUS:85130001575

SN - 1942-0862

VL - 14

JO - mAbs

JF - mAbs

IS - 1

M1 - 2072455

ER -

Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this